The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 30, 2024

Filed:

Oct. 02, 2019
Applicants:

Omeros Corporation, Seattle, WA (US);

University of Leicester, Leicestershire, GB;

Inventors:

Hans-Wilhelm Schwaeble, Cambridge, GB;

Clark E. Tedford, Poulsbo, WA (US);

James B. Parent, Bainbridge Island, WA (US);

Thomas Dudler, Bellevue, WA (US);

Gregory A. Demopulos, Mercer Island, WA (US);

Assignees:

Omeros Corporation, Seattle, WA (US);

University of Leicester, Leicester, GB;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/40 (2006.01); A61K 39/395 (2006.01); A01N 1/02 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/40 (2013.01); A01N 1/0205 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.


Find Patent Forward Citations

Loading…